Clinical trial Recruiting at 1 site Interventional Ages 19 to 60

Preoperative Maxigesic to reduce remifentanil needs during surgery

Official title: The Effect of Preoperative Maxigesic® Administration on Analgesic Nociception Index (ANI) Guided Remifentanil Administration

Run by Ajou University School of Medicine · NCT06015711 · Data updated 2026-11-12

We'll see if giving Maxigesic (intravenous ibuprofen plus acetaminophen) before general anesthesia reduces how much remifentanil adults aged 19–60 need during surgery.

Quick facts

Study typeInterventional
Ages19 Years to 60 Years
SexAll
Enrollment96 (estimated)
SponsorAjou University School of Medicine
Academic / other
Locations1 site (Suwon, Gyeonggi-do)
StatusRecruiting
StartedAugust 30, 2023
Main results expectedAugust 31, 2026
Study endsDecember 31, 2026
Registry record updatedOctober 3, 2025
Trial IDNCT06015711 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 19–60 with ASA physical status 1–3 who are scheduled for surgery under general anesthesia and have no contraindications to NSAIDs or acetaminophen.

Probably not a fit

People who are pregnant, have liver or kidney disease, asthma, NSAID or acetaminophen allergy, chronic pain or opioid dependence, active alcohol use disorder, psychiatric medication use, or a history of gastrointestinal ulcer or bleeding are excluded and unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial gives adults scheduled for general anesthesia a preoperative dose of Maxigesic (combined IV ibuprofen and acetaminophen) and records intraoperative remifentanil use. Intraoperative nociception and opioid dosing are monitored, with total remifentanil requirement as the main outcome. The Analgesia Nociception Index (ANI), a heart-rate variability–based monitor, is used to track real-time nociception during anesthesia. The study is performed at Ajou University School of Medicine in Suwon among ASA class 1–3 patients aged 19–60.

Why it matters

Potential benefit: If successful, preoperative Maxigesic could lower intraoperative opioid exposure and reduce postoperative pain and opioid-related side effects.

How similar studies have gone: Prior studies show preoperative ibuprofen or acetaminophen can reduce postoperative opioid use, but using them specifically to lower intraoperative remifentanil requirement is novel and unproven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (19-60 years old) with ASA physical status 1, 2, 3
* Scheduled surgery under general anesthesia

Exclusion Criteria:

* The patient does not conset
* Pregnancy
* hepatic disorder
* Renal disorder
* Asthma
* Hypersensitivity to the NSAIDs or acetaminophen
* Patients receiving chronic pain therapy
* Drug dependence
* Patients taking psychiatric drugs
* Alcoholics
* History of gastrointestinal ulcer or bleeding

Where it's running

  • Ajou university school of medicine
    Suwon, Gyeonggi-do, South Korea
    Recruiting

Study contacts

  • Principal investigator: In Kyong Yi, MD — Ajou University School of Medicine
  • Study coordinator: In Kyong Yi, MD
  • Email: lyrin01@gmail.com
  • Phone: +82-31-219-5579

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.